NCT03042325View on ClinicalTrials.gov

Safety and Efficacy of Alogliptin in Indian Participants With Type 2 Diabetes Mellitus

PHASE4WithdrawnINTERVENTIONAL
0
Timeline

Start Date

July 30, 2017

Primary Completion Date

January 15, 2018

Study Completion Date

January 15, 2018

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Alogliptin

Alogliptin tablets

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY

NCT03042325 - Safety and Efficacy of Alogliptin in Indian Participants With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter